Insilico Medicine, fresh from a Hong Kong IPO, signed an R&D collaboration with Servier valued at up to $888 million to discover oncology therapies using Insilico’s AI platforms. The agreement gives Insilico near‑term funding and partners Servier for clinical validation and commercialization. Variant Bio struck a research and licensing agreement with Boehringer Ingelheim focused on novel targets for kidney disease, a pact worth upfront and milestone payments totaling over $120 million. Variant Bio will apply its Inference AI platform that integrates genomic and multiomics datasets to nominate and validate targets. Together, the deals underscore Big Pharma’s continued willingness to pay for access to AI‑first discovery engines and genomic data sets, spreading risk via milestone frameworks while aiming to accelerate target selection and lead identification.